Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

Women’s health startup Evvy announced a $40 million Series B round led by Catalio Capital Management to scale its vaginal microbiome testing and research. The company, founded in 2021, operates an at-home, CLIA- and CLEP-certified metagenomic sequencing test that users submit by mail for clinician-reviewed results and care guidance.

By AI NewsroomPublished 44 minutes agoUpdated 44 minutes ago0 views

Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

Why It Matters

The funding will support building a large, linked dataset of vaginal microbiome profiles, symptoms, treatments and outcomes—data Evvy says is needed to improve precision medicine for female biology and to enable AI-driven discovery of new biomarkers. Advocates say such datasets could help address gaps in research and diagnostic tools for women's health.

Key Facts

Funding: $40 million Series B led by Catalio Capital Management
Founding year and founders: Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro
Test offering: At-home, single-swab vaginal test that Evvy says is CLIA- and CLEP-certified and uses mNGS sequencing
How the test works: Users mail swabs to Evvy's lab; results are sequenced, reviewed by clinicians on the platform, and posted to patients' health portals
Clinical support: Results include diagnosis, clinical interpretation, and next steps, including personalized prescription care when relevant

Evvy said Tuesday it has raised $40 million in a Series B round led by Catalio Capital Management to expand its work on the vaginal microbiome and related women’s health research. The Boston-based startup, founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, offers an at-home, single-swab test that the company says is CLIA- and CLEP-certified and analyzed using metagenomic next-generation sequencing (mNGS).

Customers send swabs to Evvy’s laboratory, where samples are sequenced and the results are routed to clinicians registered on Evvy’s platform for interpretation. Patients receive their results through an online health portal alongside a clinical interpretation and suggested next steps; when appropriate, that can include a personalized prescription plan, the company says.

Since launching, Evvy reports it now serves more than 100,000 patients across the United States and partners with roughly 3,000 practitioners. The company also cites a growing scientific footprint: 15 peer-reviewed publications and abstracts, identification of novel bacterial vaginosis subtypes, and discovery of hundreds of previously uncatalogued vaginal microbiome genomes.

Evvy’s stated ambition goes beyond diagnostics to building a linked dataset that connects microbiome biology with symptoms, treatments and outcomes; the company argues that such data are essential to developing more precise care for female biology. It has begun applying its platform in fertility care—running a prospective study with IVF clinics—and in May launched an AI assistant, EvvyAI, to translate microbiome results into real-time guidance while directing patients to clinicians for medical questions. Evvy’s leadership says the work could eventually produce more regular, noninvasive screening tools akin to a new kind of Pap smear and help explain conditions currently labeled as “unexplained.”

Evvy is operating within a growing field of vaginal-health startups, with competitors and peers including Juno Bio, Tiny Health and Daye. The new financing is intended to accelerate Evvy’s data collection and research efforts that the company says will inform personalized treatments and biomarker discovery for conditions ranging from recurrent pregnancy loss and IVF outcomes to infection and gynecologic cancers.